Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

News Summary: $IOVA, a small cap bio company, is seeing increasing revenues and infusions. Short sellers are warned about potential lung data results impacting stock prices. The company has initiated late trials in high lung cancer regions. Stock recovery coincided with endo trial updates. Expectations of positive lung and endo data releases in September-October. Market manipulation expected with potential red open followed by recovery. Call activity suggests confidence in company's science and therapy work.